Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPACET 100 vs ANEXSIA 7.5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.
Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.
Management of mild to moderate pain,Fever reduction,Off-label: Treatment of osteoarthritis pain (as acetaminophen)
Management of moderate to moderately severe pain where treatment with an opioid is appropriate and for which alternative treatments are inadequate
1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.
1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).
The terminal elimination half-life of acetaminophen after propacetamol administration is approximately 2–3 hours in adults with normal hepatic function. This half-life may be prolonged in patients with hepatic impairment or overdose.
Hydrocodone: 3.8-4.5 hours (immediate-release). Acetaminophen: 2-3 hours. Clinical note: Half-life prolonged in hepatic impairment; requires dose adjustment.
Rapidly hydrolyzed by plasma esterases to acetaminophen; acetaminophen is primarily metabolized by glucuronidation and sulfation, with a minor pathway via CYP2E1 to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
Hydrocodone: CYP3A4 and CYP2D6; Acetaminophen: primarily via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation, with minor oxidation by CYP2E1.
Propacet 100 (propacetamol) is a prodrug of acetaminophen. Renal elimination accounts for >90% of the administered dose, with approximately 85% as acetaminophen glucuronide and sulfate conjugates, and about 5% as unchanged acetaminophen. Biliary/fecal elimination is minimal (<5%).
Renal: ~90-100% as hydrocodone metabolites (conjugated) and unchanged hydrocodone; ~60% as acetaminophen metabolites (glucuronide, sulfate, cysteine); <5% unchanged acetaminophen. Biliary/fecal: <5%.
Acetaminophen is minimally bound to plasma proteins, with protein binding of approximately 10–25% at therapeutic concentrations. It binds primarily to albumin.
Hydrocodone: ~20-30% (albumin). Acetaminophen: ~10-25% (albumin).
The volume of distribution (Vd) of acetaminophen is approximately 0.9–1.0 L/kg, indicating distribution into total body water. This reflects its hydrophilic nature and widespread tissue penetration.
Hydrocodone: 3-4 L/kg (extensive tissue distribution). Acetaminophen: ~1 L/kg (uniformly distributed).
Propacetamol is administered intravenously; thus, bioavailability is 100%. After hydrolysis to acetaminophen, the bioavailability of active acetaminophen is essentially complete.
Oral: Hydrocodone ~70% (high first-pass metabolism); Acetaminophen ~85-90% (minimal first-pass).
GFR 30-50 m L/min: extend interval to every 8 hours; GFR <30 m L/min: extend interval to every 12 hours; hemodialysis: dose post-dialysis.
For GFR 30-59 m L/min: administer every 6 hours; maximum 4 tablets per day. For GFR 15-29 m L/min: administer every 8 hours; maximum 3 tablets per day. For GFR <15 m L/min: not recommended due to accumulation of metabolites.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use alternative analgesic.
Child-Pugh Class A: no adjustment necessary. Child-Pugh Class B: reduce dose by 25-50% and extend dosing interval to every 6-8 hours; maximum 4 tablets per day. Child-Pugh Class C: contraindicated due to risk of hepatotoxicity.
10-15 mg/kg/dose propacetamol equivalent every 6 hours; maximum 60 mg/kg/day; do not exceed adult dose.
Not recommended for pediatric patients; safety and efficacy not established for children under 18 years. For adolescents ≥18 years: adult dosing.
Initiate at lower end of dosing range (100 mg every 6 hours); maximum 800 mg/day; monitor renal and hepatic function.
Initiate at 1 tablet (hydrocodone 5 mg / acetaminophen 325 mg) every 6 hours as needed; titrate cautiously due to increased sensitivity, decreased renal function, and risk of respiratory depression. Maximum 4 tablets per day.
No FDA black box warning exists for propacetamol specifically; however, acetaminophen (active metabolite) carries a risk of severe liver injury in cases of overdose, particularly with chronic alcohol use or hepatic impairment.
Addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity due to acetaminophen.
Hepatotoxicity risk with overdose or chronic alcohol use; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely; use with caution in hepatic impairment, alcohol use disorder, or malnutrition.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use of alcohol, benzodiazepines, or other CNS depressants; hepatotoxicity; severe hypotension; adrenal insufficiency; seizures; GI obstruction; impaired mental/physical abilities; use in elderly, cachectic, or debilitated patients; renal impairment; hepatic impairment; pregnancy; labor and delivery; nursing mothers; pediatric use; driving and operating machinery.
History of hypersensitivity to acetaminophen or propacetamol; severe hepatic impairment; use of MAOIs (potential interaction).
Significant respiratory depression; acute or severe bronchial asthma; known or suspected GI obstruction; hypersensitivity to hydrocodone or acetaminophen; concomitant use of MAOIs or within 14 days of such therapy.
No specific food interactions; however, maintain adequate caloric intake to support glutathione synthesis. Avoid alcohol as it may increase hepatotoxicity risk.
Avoid alcohol consumption due to increased risk of acetaminophen hepatotoxicity and CNS depression. No specific food restrictions, but grapefruit juice may theoretically affect hydrocodone metabolism via CYP3A4 inhibition; however, clinical significance is uncertain.
Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Second and third trimesters: No known fetal toxicity at therapeutic doses; overdose may cause hepatic necrosis in mother and potentially fetus.
FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube defects. Second trimester: No major malformations except with prolonged opioid use. Third trimester: Acetaminophen safe; hydrocodone risk of neonatal opioid withdrawal syndrome (NOWS). Avoid near term.
Paracetamol is excreted into breast milk in trace amounts; milk-to-plasma ratio (M/P) is approximately 0.1-0.2. At maternal therapeutic doses, infant exposure is less than 2% of maternal weight-adjusted dose, considered compatible with breastfeeding.
Hydrocodone/acetaminophen excreted in breast milk. M/P ratio unknown. Hydrocodone relative infant dose <3% of weight-adjusted maternal dose. Acetaminophen relative infant dose <2%. Use with caution; monitor infant for sedation, apnea, poor feeding. Highest risk in CYP2D6 ultrarapid metabolizers.
Pharmacokinetic changes in pregnancy include increased clearance and volume of distribution of paracetamol, but no dose adjustment is required for Propacet 100; standard adult doses (500-1000 mg every 4-6 hours, max 4 g/day) are safe and effective.
Increased clearance of hydrocodone in pregnancy may require dose adjustment; monitor for inadequate analgesia. Acetaminophen pharmacokinetics unchanged. Avoid high doses (hepatotoxicity risk). Consider baseline hepatic function. No specific dose adjustment recommended; titrate to effect.
Propacet 100 (propacetamol, a prodrug of acetaminophen) is administered intravenously; ensure patency of IV line to prevent extravasation, which can cause injection site reactions. Contraindicated in severe hepatic impairment (Child-Pugh C) and in patients with glutathione depletion (e.g., malnutrition, sepsis). Monitor liver function tests during prolonged use. Use with caution in patients with asthma, as sulfite in formulation may trigger bronchospasm.
ANEXSIA 7.5/325 (hydrocodone/acetaminophen) carries a boxed warning for acetaminophen hepatotoxicity; maximum acetaminophen dose from all sources should not exceed 4 g/day. Hydrocodone is metabolized by CYP2D6 to hydromorphone; ultrarapid metabolizers may experience toxicity. Avoid concurrent use with other CNS depressants including alcohol. Prescribe with caution in patients with renal impairment (hydrocodone accumulation) or hepatic impairment (acetaminophen toxicity). Monitor for signs of respiratory depression, especially at therapy initiation and dose titration. Use the lowest effective dose for the shortest duration.
Propacet 100 is given intravenously for pain or fever; you must receive it in a healthcare setting.,Report any signs of allergic reaction such as rash, itching, swelling, or trouble breathing immediately.,This medication is a prodrug of acetaminophen; do not take additional acetaminophen-containing products while on this therapy.,Avoid alcohol during treatment to reduce risk of liver damage.
Do not exceed 6 tablets per day due to acetaminophen content.,Avoid alcohol while taking this medication.,Do not drive or operate heavy machinery until you know how this medication affects you.,Take exactly as prescribed; do not share with others.,Seek emergency help if you experience difficulty breathing, severe drowsiness, or signs of allergic reaction.,Store securely out of reach of children and dispose of unused medication properly.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPACET 100 vs ANEXSIA 7.5/325, answered by our medical review team.
PROPACET 100 is a Opioid analgesic combination that works by Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.. ANEXSIA 7.5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a mu-opioid receptor agonist, producing analgesia and euphoria. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and providing analgesic and antipyretic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPACET 100 and ANEXSIA 7.5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPACET 100 is: 1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.. The standard adult dose of ANEXSIA 7.5/325 is: 1 tablet (hydrocodone 7.5 mg / acetaminophen 325 mg) orally every 4 to 6 hours as needed for pain; maximum 6 tablets per day (hydrocodone 45 mg / acetaminophen 1950 mg).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPACET 100 and ANEXSIA 7.5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPACET 100 is classified as Category C. Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Seco. ANEXSIA 7.5/325 is classified as Category C. FDA Category C (hydrocodone) and Category D (acetaminophen) in third trimester. First trimester: Acetaminophen associated with rare gastroschisis; hydrocodone risk of neural tube d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.